Mauricio Moreno
Concepts (265)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Free Tissue Flaps | 10 | 2023 | 56 | 6.010 |
Why?
| Head and Neck Neoplasms | 9 | 2023 | 335 | 4.550 |
Why?
| Neck Dissection | 6 | 2021 | 43 | 1.950 |
Why?
| Neck | 4 | 2021 | 116 | 1.600 |
Why?
| Retrospective Studies | 22 | 2023 | 6432 | 1.270 |
Why?
| Length of Stay | 3 | 2019 | 683 | 1.040 |
Why?
| Postoperative Complications | 6 | 2022 | 1033 | 1.040 |
Why?
| Mandibular Reconstruction | 1 | 2023 | 10 | 0.930 |
Why?
| Middle Aged | 25 | 2023 | 13070 | 0.880 |
Why?
| Head | 2 | 2021 | 77 | 0.860 |
Why?
| Thyroidectomy | 3 | 2021 | 103 | 0.860 |
Why?
| Critical Pathways | 2 | 2019 | 36 | 0.840 |
Why?
| Intraoperative Care | 1 | 2021 | 57 | 0.820 |
Why?
| Intraoperative Complications | 2 | 2021 | 125 | 0.820 |
Why?
| Chylothorax | 1 | 2021 | 16 | 0.790 |
Why?
| Hypotension | 1 | 2021 | 67 | 0.780 |
Why?
| Carcinoma, Squamous Cell | 2 | 2022 | 384 | 0.780 |
Why?
| Vasoconstrictor Agents | 1 | 2021 | 88 | 0.770 |
Why?
| Aged, 80 and over | 13 | 2022 | 3429 | 0.760 |
Why?
| Morbidity | 1 | 2021 | 149 | 0.750 |
Why?
| Venous Thrombosis | 1 | 2021 | 102 | 0.750 |
Why?
| Paranasal Sinus Neoplasms | 2 | 2010 | 27 | 0.740 |
Why?
| Naproxen | 1 | 2019 | 8 | 0.730 |
Why?
| Orthognathic Surgical Procedures | 1 | 2019 | 2 | 0.730 |
Why?
| Mandible | 1 | 2019 | 24 | 0.710 |
Why?
| Reoperation | 1 | 2021 | 454 | 0.710 |
Why?
| Thyroid Neoplasms | 2 | 2012 | 162 | 0.690 |
Why?
| Edema | 1 | 2019 | 74 | 0.680 |
Why?
| Health Status Indicators | 1 | 2019 | 94 | 0.670 |
Why?
| Male | 26 | 2023 | 27312 | 0.660 |
Why?
| Female | 28 | 2023 | 28418 | 0.660 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 142 | 0.650 |
Why?
| Health Resources | 1 | 2019 | 80 | 0.640 |
Why?
| Humans | 41 | 2023 | 54246 | 0.640 |
Why?
| Aged | 19 | 2021 | 10041 | 0.630 |
Why?
| Academic Medical Centers | 2 | 2019 | 141 | 0.620 |
Why?
| Thigh | 2 | 2015 | 40 | 0.590 |
Why?
| Laryngectomy | 2 | 2014 | 28 | 0.580 |
Why?
| Adult | 18 | 2021 | 14182 | 0.570 |
Why?
| Melanoma | 2 | 2010 | 313 | 0.570 |
Why?
| Treatment Outcome | 15 | 2021 | 5604 | 0.560 |
Why?
| Surgical Flaps | 2 | 2023 | 135 | 0.550 |
Why?
| Patient Discharge | 2 | 2019 | 353 | 0.540 |
Why?
| Databases, Factual | 2 | 2019 | 684 | 0.530 |
Why?
| Carcinoma, Papillary | 2 | 2012 | 65 | 0.480 |
Why?
| Video-Assisted Surgery | 1 | 2013 | 3 | 0.470 |
Why?
| Parathyroidectomy | 2 | 2012 | 75 | 0.460 |
Why?
| Tissue and Organ Harvesting | 1 | 2013 | 27 | 0.460 |
Why?
| Soft Tissue Injuries | 1 | 2013 | 22 | 0.450 |
Why?
| Neck Injuries | 1 | 2013 | 26 | 0.450 |
Why?
| Endoscopy | 1 | 2013 | 131 | 0.430 |
Why?
| Speech, Esophageal | 1 | 2010 | 1 | 0.400 |
Why?
| Palatal Obturators | 1 | 2010 | 2 | 0.380 |
Why?
| Maxilla | 1 | 2010 | 29 | 0.380 |
Why?
| Carcinoma, Merkel Cell | 3 | 2016 | 47 | 0.370 |
Why?
| Parathyroid Neoplasms | 1 | 2010 | 44 | 0.370 |
Why?
| Nose Neoplasms | 1 | 2010 | 10 | 0.370 |
Why?
| Nasal Mucosa | 1 | 2010 | 22 | 0.370 |
Why?
| Preoperative Care | 1 | 2011 | 184 | 0.350 |
Why?
| Adolescent | 9 | 2019 | 6885 | 0.340 |
Why?
| Adenoma | 1 | 2010 | 142 | 0.340 |
Why?
| Follow-Up Studies | 6 | 2023 | 2387 | 0.330 |
Why?
| Graft Survival | 2 | 2019 | 165 | 0.320 |
Why?
| Young Adult | 7 | 2019 | 4308 | 0.320 |
Why?
| Neoplasm Recurrence, Local | 3 | 2022 | 644 | 0.310 |
Why?
| Colitis, Ulcerative | 2 | 2018 | 52 | 0.300 |
Why?
| Radiotherapy, Adjuvant | 3 | 2019 | 66 | 0.300 |
Why?
| Crohn Disease | 2 | 2018 | 96 | 0.290 |
Why?
| Pain, Postoperative | 3 | 2022 | 161 | 0.260 |
Why?
| Skin Neoplasms | 3 | 2016 | 532 | 0.260 |
Why?
| Comorbidity | 2 | 2019 | 663 | 0.250 |
Why?
| TOR Serine-Threonine Kinases | 2 | 2016 | 85 | 0.250 |
Why?
| Adenocarcinoma | 2 | 2023 | 428 | 0.250 |
Why?
| Prognosis | 3 | 2019 | 2118 | 0.240 |
Why?
| Adenoma, Pleomorphic | 1 | 2023 | 7 | 0.240 |
Why?
| Carcinoma, Ductal | 1 | 2023 | 8 | 0.240 |
Why?
| Paranasal Sinuses | 1 | 2023 | 25 | 0.230 |
Why?
| Salivary Gland Neoplasms | 1 | 2023 | 24 | 0.230 |
Why?
| Scapula | 1 | 2023 | 19 | 0.230 |
Why?
| Forearm | 1 | 2023 | 41 | 0.230 |
Why?
| Ambulatory Care Facilities | 1 | 2023 | 136 | 0.220 |
Why?
| Sinusitis | 1 | 2023 | 60 | 0.220 |
Why?
| Tramadol | 1 | 2022 | 29 | 0.220 |
Why?
| Ambulatory Care | 1 | 2023 | 229 | 0.210 |
Why?
| Microsurgery | 1 | 2021 | 35 | 0.210 |
Why?
| Anastomosis, Surgical | 1 | 2021 | 72 | 0.210 |
Why?
| Recurrent Laryngeal Nerve Injuries | 1 | 2021 | 11 | 0.210 |
Why?
| Salvage Therapy | 1 | 2022 | 145 | 0.200 |
Why?
| Gastrointestinal Agents | 2 | 2018 | 36 | 0.200 |
Why?
| Infusions, Intravenous | 1 | 2021 | 231 | 0.200 |
Why?
| Indocyanine Green | 2 | 2011 | 39 | 0.200 |
Why?
| Drug Administration Schedule | 1 | 2021 | 401 | 0.190 |
Why?
| Robotics | 1 | 2021 | 45 | 0.190 |
Why?
| Laser Therapy | 2 | 2011 | 91 | 0.190 |
Why?
| Cohort Studies | 2 | 2019 | 1543 | 0.190 |
Why?
| Odds Ratio | 1 | 2021 | 604 | 0.180 |
Why?
| Reproducibility of Results | 4 | 2023 | 1304 | 0.180 |
Why?
| Analgesics, Opioid | 2 | 2022 | 501 | 0.180 |
Why?
| Acetaminophen | 1 | 2022 | 349 | 0.170 |
Why?
| Ultrasonography | 2 | 2012 | 480 | 0.170 |
Why?
| Neoplasm Staging | 3 | 2010 | 806 | 0.170 |
Why?
| Combined Modality Therapy | 2 | 2012 | 692 | 0.170 |
Why?
| Drug Monitoring | 1 | 2018 | 85 | 0.160 |
Why?
| Hospital Costs | 1 | 2019 | 84 | 0.160 |
Why?
| Postoperative Care | 1 | 2019 | 121 | 0.160 |
Why?
| Graft Rejection | 1 | 2019 | 161 | 0.160 |
Why?
| Analysis of Variance | 1 | 2019 | 635 | 0.150 |
Why?
| Heart Defects, Congenital | 1 | 2023 | 608 | 0.150 |
Why?
| Patient Readmission | 1 | 2019 | 242 | 0.150 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 240 | 0.140 |
Why?
| Benzoxazoles | 1 | 2016 | 12 | 0.140 |
Why?
| Prospective Studies | 4 | 2022 | 2604 | 0.140 |
Why?
| Proto-Oncogene Proteins c-myb | 1 | 2015 | 9 | 0.130 |
Why?
| United States | 2 | 2019 | 5200 | 0.130 |
Why?
| Cell Proliferation | 2 | 2016 | 1096 | 0.130 |
Why?
| Pyrimidines | 1 | 2016 | 196 | 0.120 |
Why?
| Regression Analysis | 2 | 2012 | 445 | 0.120 |
Why?
| Nuclear Proteins | 1 | 2015 | 252 | 0.120 |
Why?
| Child | 4 | 2018 | 7337 | 0.110 |
Why?
| Skin Transplantation | 1 | 2013 | 50 | 0.110 |
Why?
| Arkansas | 1 | 2019 | 2094 | 0.110 |
Why?
| Apoptosis | 2 | 2016 | 1300 | 0.110 |
Why?
| Osteocalcin | 1 | 2012 | 46 | 0.110 |
Why?
| Quality of Life | 1 | 2019 | 922 | 0.110 |
Why?
| Survival | 1 | 2012 | 16 | 0.110 |
Why?
| Equipment Design | 1 | 2013 | 318 | 0.110 |
Why?
| Leukoplakia, Oral | 1 | 2011 | 8 | 0.100 |
Why?
| Aminolevulinic Acid | 1 | 2011 | 10 | 0.100 |
Why?
| Iodine Radioisotopes | 1 | 2012 | 43 | 0.100 |
Why?
| Lasers, Dye | 1 | 2011 | 10 | 0.100 |
Why?
| Recurrence | 2 | 2012 | 690 | 0.100 |
Why?
| Hyperparathyroidism, Primary | 1 | 2012 | 50 | 0.100 |
Why?
| Decision Support Techniques | 1 | 2012 | 74 | 0.100 |
Why?
| Photosensitizing Agents | 1 | 2011 | 24 | 0.100 |
Why?
| Epigenesis, Genetic | 1 | 2015 | 399 | 0.100 |
Why?
| Infrared Rays | 1 | 2011 | 27 | 0.100 |
Why?
| Dose-Response Relationship, Radiation | 1 | 2012 | 204 | 0.100 |
Why?
| Photochemotherapy | 1 | 2011 | 37 | 0.100 |
Why?
| Thyroid Gland | 2 | 2022 | 93 | 0.100 |
Why?
| Biopsy, Fine-Needle | 1 | 2012 | 116 | 0.100 |
Why?
| Hospital Mortality | 1 | 2014 | 465 | 0.100 |
Why?
| Fascia | 1 | 2010 | 6 | 0.100 |
Why?
| Transcription Factors | 1 | 2015 | 622 | 0.100 |
Why?
| Lymph Node Excision | 1 | 2012 | 140 | 0.100 |
Why?
| Laser Coagulation | 1 | 2011 | 27 | 0.100 |
Why?
| Coloring Agents | 1 | 2011 | 84 | 0.100 |
Why?
| Tongue Neoplasms | 1 | 2010 | 13 | 0.100 |
Why?
| Speech Intelligibility | 1 | 2010 | 15 | 0.090 |
Why?
| Veins | 1 | 2011 | 74 | 0.090 |
Why?
| Carcinoma | 1 | 2012 | 153 | 0.090 |
Why?
| Parathyroid Hormone | 1 | 2012 | 196 | 0.090 |
Why?
| Kaplan-Meier Estimate | 1 | 2012 | 514 | 0.090 |
Why?
| Mammary Neoplasms, Experimental | 1 | 2011 | 135 | 0.090 |
Why?
| Deglutition | 1 | 2010 | 37 | 0.090 |
Why?
| Vascular Diseases | 1 | 2011 | 77 | 0.090 |
Why?
| Disease-Free Survival | 1 | 2011 | 485 | 0.090 |
Why?
| Survival Analysis | 1 | 2012 | 735 | 0.090 |
Why?
| Tracheostomy | 1 | 2010 | 81 | 0.090 |
Why?
| Lymph Nodes | 1 | 2012 | 284 | 0.090 |
Why?
| Quality Indicators, Health Care | 1 | 2010 | 99 | 0.090 |
Why?
| Risk Assessment | 1 | 2014 | 1361 | 0.080 |
Why?
| Guideline Adherence | 1 | 2010 | 147 | 0.080 |
Why?
| Predictive Value of Tests | 1 | 2012 | 1048 | 0.080 |
Why?
| Survival Rate | 1 | 2010 | 951 | 0.080 |
Why?
| Positron-Emission Tomography | 1 | 2010 | 322 | 0.080 |
Why?
| Pneumothorax, Artificial | 1 | 2007 | 1 | 0.080 |
Why?
| Urologic Surgical Procedures | 1 | 2007 | 28 | 0.080 |
Why?
| Diaphragm | 1 | 2007 | 29 | 0.070 |
Why?
| Models, Biological | 1 | 2011 | 823 | 0.070 |
Why?
| Disease Progression | 1 | 2010 | 913 | 0.070 |
Why?
| Severity of Illness Index | 3 | 2018 | 1084 | 0.070 |
Why?
| Atrioventricular Node | 1 | 2006 | 5 | 0.070 |
Why?
| Tachycardia, Ectopic Atrial | 1 | 2006 | 3 | 0.070 |
Why?
| Cryosurgery | 1 | 2006 | 38 | 0.070 |
Why?
| Azepines | 2 | 2016 | 22 | 0.070 |
Why?
| Pulmonary Veins | 1 | 2005 | 31 | 0.070 |
Why?
| Pilot Projects | 2 | 2022 | 808 | 0.070 |
Why?
| Xenograft Model Antitumor Assays | 2 | 2016 | 219 | 0.060 |
Why?
| Risk Factors | 1 | 2014 | 3930 | 0.060 |
Why?
| Laparoscopy | 1 | 2007 | 188 | 0.060 |
Why?
| Triazoles | 2 | 2016 | 120 | 0.060 |
Why?
| Salivary Ducts | 1 | 2023 | 5 | 0.060 |
Why?
| Parotid Gland | 1 | 2023 | 16 | 0.060 |
Why?
| Facial Bones | 1 | 2023 | 22 | 0.060 |
Why?
| Ubiquitin Thiolesterase | 1 | 2023 | 23 | 0.060 |
Why?
| Ibuprofen | 1 | 2022 | 28 | 0.060 |
Why?
| Atrial Fibrillation | 1 | 2005 | 197 | 0.060 |
Why?
| Tumor Suppressor Proteins | 1 | 2023 | 141 | 0.050 |
Why?
| Recurrent Laryngeal Nerve | 1 | 2021 | 20 | 0.050 |
Why?
| Laryngeal Nerves | 1 | 2021 | 19 | 0.050 |
Why?
| Glossectomy | 1 | 2021 | 6 | 0.050 |
Why?
| Tongue | 1 | 2021 | 41 | 0.050 |
Why?
| Arteries | 1 | 2021 | 101 | 0.050 |
Why?
| Immunohistochemistry | 1 | 2023 | 1089 | 0.050 |
Why?
| Cell Line, Tumor | 2 | 2015 | 1550 | 0.050 |
Why?
| Pain Management | 1 | 2021 | 155 | 0.040 |
Why?
| Mice | 3 | 2016 | 6413 | 0.040 |
Why?
| Statistics, Nonparametric | 1 | 2018 | 232 | 0.040 |
Why?
| Colonoscopy | 1 | 2018 | 105 | 0.040 |
Why?
| Reference Values | 1 | 2018 | 354 | 0.040 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 314 | 0.040 |
Why?
| Tomography, X-Ray Computed | 1 | 2023 | 1213 | 0.040 |
Why?
| Chile | 1 | 2016 | 4 | 0.040 |
Why?
| Immunotherapy | 1 | 2018 | 263 | 0.040 |
Why?
| Enterocolitis, Pseudomembranous | 1 | 2016 | 25 | 0.040 |
Why?
| Age of Onset | 1 | 2016 | 116 | 0.030 |
Why?
| Digestive System Surgical Procedures | 1 | 2016 | 35 | 0.030 |
Why?
| Age Distribution | 1 | 2016 | 198 | 0.030 |
Why?
| Mice, Inbred NOD | 1 | 2016 | 99 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2016 | 165 | 0.030 |
Why?
| Mice, SCID | 1 | 2016 | 196 | 0.030 |
Why?
| Drug Synergism | 1 | 2016 | 171 | 0.030 |
Why?
| Jumonji Domain-Containing Histone Demethylases | 1 | 2015 | 18 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 206 | 0.030 |
Why?
| Acetylation | 1 | 2015 | 99 | 0.030 |
Why?
| Tumor Cells, Cultured | 1 | 2016 | 477 | 0.030 |
Why?
| Enhancer Elements, Genetic | 1 | 2015 | 64 | 0.030 |
Why?
| Drug Therapy, Combination | 1 | 2016 | 426 | 0.030 |
Why?
| Neoplasm Metastasis | 1 | 2015 | 252 | 0.030 |
Why?
| Immunosuppressive Agents | 1 | 2016 | 248 | 0.030 |
Why?
| Blotting, Western | 1 | 2016 | 683 | 0.030 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 673 | 0.030 |
Why?
| Chromatin | 1 | 2015 | 156 | 0.030 |
Why?
| Animals | 3 | 2016 | 14385 | 0.030 |
Why?
| Amino Acid Chloromethyl Ketones | 1 | 2013 | 17 | 0.030 |
Why?
| Referral and Consultation | 1 | 2016 | 307 | 0.030 |
Why?
| Tissue Fixation | 1 | 2013 | 35 | 0.030 |
Why?
| Phagosomes | 1 | 2013 | 21 | 0.030 |
Why?
| Paraffin Embedding | 1 | 2013 | 56 | 0.030 |
Why?
| Formaldehyde | 1 | 2013 | 49 | 0.030 |
Why?
| Cell Cycle Proteins | 1 | 2015 | 199 | 0.030 |
Why?
| Registries | 1 | 2016 | 553 | 0.030 |
Why?
| Caspases | 1 | 2013 | 146 | 0.030 |
Why?
| Enzyme Activation | 1 | 2013 | 329 | 0.030 |
Why?
| Protein Binding | 1 | 2015 | 736 | 0.030 |
Why?
| Promoter Regions, Genetic | 1 | 2015 | 520 | 0.030 |
Why?
| Preoperative Period | 1 | 2012 | 59 | 0.030 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1056 | 0.030 |
Why?
| RNA, Messenger | 1 | 2016 | 1202 | 0.030 |
Why?
| Protein Kinase Inhibitors | 1 | 2013 | 216 | 0.030 |
Why?
| Administration, Topical | 1 | 2011 | 71 | 0.030 |
Why?
| Hospitalization | 1 | 2016 | 705 | 0.030 |
Why?
| Up-Regulation | 1 | 2013 | 508 | 0.030 |
Why?
| Postoperative Period | 1 | 2012 | 189 | 0.030 |
Why?
| Cell Survival | 1 | 2013 | 657 | 0.030 |
Why?
| Injections, Intravenous | 1 | 2011 | 148 | 0.020 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 866 | 0.020 |
Why?
| Cancer Care Facilities | 1 | 2010 | 21 | 0.020 |
Why?
| Multivariate Analysis | 1 | 2012 | 643 | 0.020 |
Why?
| Leg | 1 | 2011 | 130 | 0.020 |
Why?
| Lasers | 1 | 2011 | 141 | 0.020 |
Why?
| Quality Assurance, Health Care | 1 | 2010 | 164 | 0.020 |
Why?
| Time Factors | 1 | 2016 | 3212 | 0.020 |
Why?
| Biopsy | 1 | 2011 | 692 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2011 | 1476 | 0.020 |
Why?
| Child, Preschool | 1 | 2016 | 4146 | 0.020 |
Why?
| Carbon Dioxide | 1 | 2007 | 102 | 0.020 |
Why?
| Atrial Function | 1 | 2005 | 7 | 0.020 |
Why?
| Secondary Prevention | 1 | 2006 | 89 | 0.020 |
Why?
| Electrocardiography, Ambulatory | 1 | 2005 | 25 | 0.020 |
Why?
| Angiography | 1 | 2005 | 147 | 0.020 |
Why?
| Heart Rate | 1 | 2006 | 357 | 0.020 |
Why?
| Electrocardiography | 1 | 2006 | 290 | 0.020 |
Why?
| Catheter Ablation | 1 | 2005 | 131 | 0.010 |
Why?
| Logistic Models | 1 | 2005 | 990 | 0.010 |
Why?
|
|
Moreno's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|